Gilead Reports Results of Biktarvy for the Treatment of HIV-1 in Adults (Treatment Naive)
Shots:
- The P-III 1489 study has assessed Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) in ratio (1:1) to treat HIV-1 infection in adults for 96 weeks- testing safety and efficacy
- P-III 1489 study results ((abacavir/dolutegravir/lamivudine (600/50/300mg- ABC/DTG/3TC) or Biktarvy): meGFR @96wks. (-7.8 mL/min vs. -9.6 mL/min); mean percent changes from baseline in spine and hip bone mineral density (spine: -0.71 vs. -0.22) (hip: -1.13 vs. -1.26); was well tolerated
- Bictegravir is a fixed dose drug containing 50 mg bictegravir- 200 mg emtricitabine- and 25 mg tenofovir alafenamide currently evaluated for the treatment naïve HIV-1 infection in adults
Ref: Gilead | Image: Gilead
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com